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Clinical Impact of Single Nucleotide 
Polymorphism in PD-L1 on 
Response to Nivolumab for 
Advanced Non-Small-Cell Lung 
Cancer Patients
Takashi Nomizo, Hiroaki Ozasa, Takahiro Tsuji, Tomoko Funazo, Yuto Yasuda, 
Hironori Yoshida, Yoshitaka Yagi, Yuichi Sakamori, Hiroki Nagai, Toyohiro Hirai & 
Young Hak Kim
This study was intended to determine the efficacy of nivolumab, we evaluated treatment response 
with respect to PD-1/PD-L1 SNPs among patients with NSCLC. A total of 50 patients with NSCLC were 
treated with nivolumab and were also evaluated for PD-1/PD-L1 single nucleotide polymorphisms 
(SNPs) from plasma DNA. We investigated the association among PD-1/PD-L1 SNPs, objective response 
rate (ORR) and progression-free survival (PFS). Two of seven SNPs studied showed association with 
ORR and PFS, with maximum evidence at the marker rs2282055. The ORR was 25%, 15%, and 0% for 
the G/G, G/T and T/T genotypes of PD-L1 rs2282055, respectively. The G allele of PD-L1 rs2282055 was 
significantly associated with better clinical response compared with the T allele (P = 0.0339 [Cochran-
Armitage trend test]). The median PFS time was 2.6 months (95% confidence interval [CI], 1.8 months 
to 4.3 months) for the G/G and G/T genotypes and 1.8 months (95% confidence interval [CI], 0.4 months 
to 2.2 months) for the T/T genotype (P = 0.0163). Moreover, the C/C and C/G genotypes of PD-L1 
rs4143815 were significantly associated with better ORR and PFS in NSCLC patients treated with 
nivolumab. These results suggest that rs2282055 and rs4143815 may be a biomarker for the efficacy of 
nivolumab.
Although lung cancer remains a major cause of cancer-related mortality worldwide, targeted therapies and immu-
notherapy contribute to better clinical outcome in non–small-cell lung cancer (NSCLC) patients1. Nivolumab, a 
fully human IgG4 programmed death 1 (PD-1) immune checkpoint inhibitor antibody, targets the PD-L1 protein 
and has demonstrated improved patient survival over docetaxel in previously treated advanced NSCLC2,3. It was 
approved by the U.S. Food and Drug Administration for treating lung cancer in October 2015 and approved for 
second-line treatment after platinum-based first-line chemotherapy. The PD-1 receptor expressed on activated 
T-cells interacts with the tumor-expressing ligands PD-L1 and PD-L2 to down-regulate the T-cell-promoted 
tumor immune escape mechanism2–4. Nivolumab binds to PD-1 and inhibits the binding of the receptor to its 
ligands PD-L1 and PD-L2 on tumor cells, and inhibits the co-inhibitory signals on T-cells5. This leads to the 
attenuation of T-cell suppression and induces antitumor responses.
Some patients with lung cancer show marked responses to nivolumab, whereas others do not respond (ORR 
~20%). It is currently difficult to predict treatment response to nivolumab since there are no precise biomarkers 
for it. Expression of PD-L1 in the tumor microenvironment is thought to be crucial for therapeutic activity6; 
however, further investigations suggest that the expression of PD-L1 is not an ideal biomarker since the PD-L1 
expression assessed by immunohistochemistry and the associated response to immune checkpoint inhibitors 
are not always concordant7,8. The expression of PD-L1 may not predict therapeutic efficacy because the inter-
actions between PD-1 and PD-L1 on B-cells link the adaptive and innate immune systems, which may explain 
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the changes in PD-1/PD-L1 response to cancer during cancer treatment9. Furthermore, it is difficult to compare 
PD-L1 expression levels among various studies since different immunohistochemistry detection antibodies for 
PD-L1 staining are used and specific PD-L1 expression cut-off levels vary among these studies10. T-cell receptor 
clonality11, co-expression of other immunologic markers12, somatic mutational burden13, and PD-L1-expressing 
circulating tumor cells14 are also candidate biomarkers for the PD-L1 blockade therapy; however, these alterna-
tives are lacking in conclusive evidence.
Recently, the application of next-generation sequencing (NGS) has emphasized the potential role of somatic 
DNA sequence markers, which may be used as independent markers, novel therapeutic targets, or as tools to 
refine expression markers15. Similarly, progress in specific and genome-wide single nucleotide polymorphisms 
(SNP) arrays have underlined the role of germline mutations in modifying cancer and treatment outcome16. 
Several studies have indicated that genetic polymorphism was correlated with clinical outcome in NSCLC17. 
Moreover, some studies have reported monochronal antibody therapy to be related with polymorphisms of the 
target molecule’s gene, for example, CTLA4 polymorphism with antiCTLA418,19, CD52 with alemtuzmab20, Il-6 
or C1qA with rituximab21,22, and Fc gamma receptor 3a with ofatumumab23. Therefore, we hypothesized that 
germline PD-1/PD-L1 SNPs might be a predictive biomarker. Some SNPs of PD-1/PD-L1 were previously shown 
to have clinical importance to diseases such as Addison’s disease24, gastric adenocarcinoma25, NSCLC26, and type 
1 diabetes27. Furthermore, a recently reported study suggested the association between a PD-L1 single nucleotide 
polymorphism and the efficacy of first-line paclitaxel-cisplatin chemotherapy28. In this study, we hypothesized 
that polymorphisms of the PD-L1 gene may alter the immune checkpoint function, thereby influencing clinical 
outcomes of response to immune checkpoint inhibitors in patients with lung cancer. We analyzed the association 
between polymorphism in the PD-L1 and PD-1 genes and clinical response to nivolumab in NSCLC patients.
Results
Patient Characteristics and Clinical Outcome. Patient characteristics are listed in Table 1. The 
median age was 65 years (40 to 80 years), and 34 patients (68%) were men. Fifty patients (100%) had an Eastern 
Cooperative Oncology Group (ECOG) performance status of 0 or 1. Forty patients (80%) were histologically 
diagnosed with adenocarcinoma and 10 patients were diagnosed with squamous cell carcinoma. Nivolumab was 
administered to all patients; 10 patients (20%) received the drug as the second-line treatment and 40 patients 
(80%) received it as the third-line treatment or beyond.
Among the 50 patients, 8 (16%) had PR, 16 (32%) had stable disease (SD), 26 (52%) had PD (Table 1), and 
none had obtained complete response. Objective responses were observed in 8 (16%) patients. The ORR for this 
study was similar to those observed in recent large clinical trials of nivolumab in NSCLC2,3. The median PFS time 
Characteristics
No. of Patients 





Total Patients 50 8 16.0
 Partial Response (PR) 8
 Stable Disease (SD) 16
 Progression of Disease (PD) 26
Median Age, (Range) 65 (40–80)
Sex 1.000*
 Male 34 7 20.6





 Never 15 1 6.7
 Ever 35 7 20.0
Histology 0.665*
 Adenocarcinoma 40 6 15.0
 EGFR-mutated (13 2 15.4)
 Squamous Cell Carcinoma 10 2 20.0
Stage




 Second 10 2 20.0
 ≥ Third 40 6 15.0
Table 1.  Patient Characteristics. Abbreviations: PS, performance status. *P values are estimated by Fisher’s 
exact test.
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in all patients was 2.2 months (95% confidence interval [CI], 1.8 to 3.3 months). The ORR was not significantly 
associated with age, gender, smoking status, histology or treatment line of nivolumab.
Associations Between Genotypes and Clinical Outcome. Five PD-L1 SNPs and two PD-1 SNPs were 
genotyped in 50 NSCLC patients who were administered with nivolumab. The SNP genotype, gene information, 
genotype frequency, and the associated clinical response are shown in Table 2. The G allele of PD-L1 rs2282055 
and the C allele of PD-L1 rs4143815 were significantly associated with better clinical response compared to the 
T allele of rs2282055 (P = 0.0339, Cochran-Armitage trend test) and to the G allele of rs4143815 (P = 0.0319, 
Cochran-Armitage trend test), respectively. No significant association between genotypes and ORR was observed 
for the remaining SNPs.
Association of PD-L1 rs4143815 with PFS. Of the 50 patients treated with nivolumab, 12 were G/G 
(24%), 15 were C/C (30%), and 23 were C/G (46%) of PD-L1 rs4143815. Genotype was not associated with 
clinicopathologic variables (Table 3). The C/C genotype was more associated with treatment effect compared to 
both C/G and G/G genotypes. Objective responses were observed in 4 of 15 (27%), 4 of 23 (17%), and none of 
12 (0%) patients of PD-L1 rs4143815 genotypes C/C, C/G and G/G, respectively. Kaplan-Meier survival curves 
(Fig. 1A) also show associations of PFS among patients with the C/C, C/G, and G/G genotypes. The median PFS 
time was 2.6 months (95% confidence interval [CI], 1.8 months to 6.1 months) for the C/C and C/G genotypes 
and 2.1 months (95% confidence interval [CI], 0.9 months to 3.0 months) for the G/G genotype (P = 0.0438). As 
shown in Fig. 2, patients with the C/C and C/G genotypes of PD-L1 rs4143815 showed slightly better responses 
to nivolumab.
Association of PD-L1 rs2282055 with PFS. We also assessed PFS among the PD-L1 rs2282055 gen-
otypes. Objective responses were observed in 5 of 20 (25%), 3 of 20 (15%), and none of 10 patients of PD-L1 
rs2282055 genotypes G/G, G/T and T/T, respectively (Table 3). Kaplan-Meier curves showed significant differ-









rs1411262 PD-L1 intron T 0.0751
T/T 15 4 24
T/C 21 3 14
C/C 14 1 7
rs2282055 PD-L1 intron T 0.0339
T/T 10 0 0
T/G 20 3 15
G/G 20 5 25
rs4143815 PD-L1 3′ UTR G 0.0319
G/G 12 0 0
G/C 23 4 17
C/C 15 4 27
rs2890658 PD-L1 intron C 0.2088
C/C 33 6 18
C/A 14 2 14
A/A 3 0 0
rs822339 PD-L1 intron G 0.0855
G/G 14 1 7
G/A 21 3 14
A/A 15 4 27
rs2227981 PD-1 synonymous G 0.1428
G/G 26 3 12
G/A 21 4 19
A/A 3 1 33
rs2227982 PD-1 missense G 0.3628
G/G 15 4 27
G/A 22 1 5
A/A 13 3 23
Table 2.  Association of PD-L1 and PD-1 Genotypes with Clinical Response. Abbreviations: ORR, objective 
response rate; †Exact test of Cochran-Armitage trend test across genotypes.
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interval [CI], 1.8 months to 4.3 months) for the G/G and G/T genotypes and 1.8 months (95% confidence interval 
[CI], 0.4 months to 2.2 months) for the T/T genotype (P = 0.0163).
Haplotype analysis. Three polymorphism of the PD-L1 gene, rs822339, rs2282055, and rs1411262, 
were generally under strong linkage disequilibrium (LD) from the pairwise disequilibrium map (LD map) 
Characteristics
rs4143815 rs2282055
No. of Patients (N = 50) (%) No. of Patients (N = 50) (%)
C/C C/G G/G P* A/A A/C C/C P*












 Male 11 17 6 n.s. 6 16 12 n.s.
 Female 4 6 6 n.s. 4 4 8 n.s.
PS
 0–1 15 23 12 n.s. 10 20 20 n.s.
 2–3 0 0 0 0 0 0
Histology
 Adeno 13 15 12 n.s. 8 16 13 n.s.
 EGFR-mutated 6 4 3 n.s. 3 4 6 n.s.
 Squamous 2 8 0 n.s. 2 3 5 n.s.
Stage
 I or II 0 0 0 0 0 0
 IIIB/IV 15 23 12 n.s. 10 20 20 n.s.
Treatment Line
 First 0 0 0 0 0 0
 Second 5 2 3 n.s. 2 1 7 n.s.
 ≥ Third 10 21 8 n.s. 8 19 13 n.s.
Treatment Response
 PR 4 4 0 0 3 5
 SD 3 9 4 4 5 7
 PD 8 10 8 6 12 8
 ORR, % 36 17 0 0.0319 0 15 25 0.0339
 DCR, % 47 57 33 n.s. 40 40 60 n.s.
Table 3.  Clinical Characteristics According to PD-L1 rs4143815 and rs2282055. Abbreviations: PS, 
performance status; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response 
rate; DCR, disease control rate; n.s, not significant. P values indicate whether the group is equally distributed 
across the subcategories using analysis of variance, and Cochrane-Armitage test, where appropriate.

















































Figure 1. Kaplan-Meier curves of PFS after administration of nivolumab, stratified by the genotype PD-L1 
rs4143815 (A) and rs2282055 (B). Symbols denote censored observations. The differences between the groups 
were evaluated using the log-rank test. Multivariate Cox proportional hazards models were used to estimate 
adjusted hazard ratios (HR) with 95% confidence intervals.
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(Supplementary Fig. S1). The two SNPs, rs2282055 and rs4143815, were in LD (|D’| = 0.624 and r2 = 0.292) in 
this study. In the PD-1 gene, the D’ value and r2 between rs2227981 and rs2227982 were |D’| = 1.0 and r2 = 0.355, 
respectively.
Discussion
We assessed the efficacy of nivolumab according to PD-1/PD-L1 SNPs. Interestingly, our study showed that 
patients with the C/C or C/G genotype of PD-L1 rs4143815 and the G/G or G/T genotypes of rs2282055 had a 
significantly longer PFS with nivolumab treatment than patients with the G/G genotype and T/T genotype respec-
tively. In addition, none of the patients obtained treatment effect with the G/G genotype of PD-L1 rs4143815 and 
the T/T genotype of rs2282055.
Currently, since the known candidate biomarkers of nivolumab mainly originate from the tumor itself and the 
surrounding tumor environment, it was suggested that the PD-L1 expression in tumor cells measured by immu-
nohistochemistry may predict responses to immune checkpoint inhibitors6,29. A meta-analysis indicated that the 
benefit from PD-1 inhibitors versus docetaxel in second-line treatment of NSCLC is limited to the PD-L1 > 1% 
subpopulation30. However, tumors that do not express detectable levels of PD-L1 on the cell surface can also 
respond to immune checkpoint inhibitors. A recent study reported that PD-L1 expression changes during the 
course of clinical treatment31, which suggests that the PD-L1 expression measured by immunohistochemis-
try cannot be solely used as the predictive treatment biomarker. A better biomarker for predicting response to 
nivolumab is required to help clinical decision-making and potentially help expose fewer patients to inadequate 
treatments and their associated toxicities and costs.
PD-L1 rs4143815, which is located in the 3′ -untranslated region (UTR) and binds to miR-57025,32, has been 
suggested by several studies to have medical significance. The C/C genotype of PD-L1 rs4143815 is associated 
with increased risk of gastric cancer due to its interference with the miR-570 function and by possibly suppress-
ing the immunological tumor restriction through increasing PD-L1 expression25. S. Lee and colleagues reported 
that the C/C genotype of PD-L1 rs4145815 is associated with worse clinical outcomes for patients who have been 
administered first-line paclitaxel-cisplatin chemotherapy28 due to the unstable binding of miRNAs to PD-L1 
mRNA, which is caused by the increased minimum free energy produced from the RNAhybrid. The G/G gen-
otype of PD-L1 rs4143815 is associated with type 1 diabetes and has also been observed with lower serum lev-
els of the PD-L1 protein in patients27. In addition, X. Shi and colleagues have recently reported that patients 
who underwent liver transplantation and received a donor liver carrying the C allele of PD-L1 rs4143815 had 
a decreased risk in developing late acute rejection33. They also found that hepatic BDCA1-positive dendritic 
cells with the rs4143815 C/C genotype showed higher PD-L1 expression than those with the G/G genotype after 
IFN-gamma stimulation33. These studies suggest that the C allele of PD-L1 rs4143815 increases PD-L1 expression 
by attenuating the miR-570 function. These findings could explain the reason why patients with the G/G genotype 
of PD-L1 rs4143815 did not respond to nivolumab in our study. Therefore, the genotypes of PD-L1 rs4143815 
may predict the level of expression of PD-L1 on the cell surface throughout the course of treatment. Moreover, 
a recent study suggested that the disruption of the PD-L1 3′ -UTR, which is caused by the structural variation of 
the gene transformation of the PD-L1 3′ -UTR region, increases PD-L1 expression and leads to immune escape 
of tumor cells34. The mechanism for immune escape, which occurs during tumor growth35, involves the avoid-
ance of first tumor antigen recognition by B-cells and unresponsive general cytotoxic T lymphocytes (CTL). By 
increasing PD-L1 expression levels and thereby down-regulating T-cell response, the C/C genotype of PD-L1 
rs4143815 may be involved in the escape from immunosurveillance. Previous report showed that Grave dis-
ease and Addison’s disease related to rs2282055, but the function of PD-L1 rs2282055 is unknown24. The two 
SNPs, rs2282055 and rs4143815, were in relatively weak LD (r2 < 0.8). This might explain the clinical significance 
of PD-L1 rs2282055. Conversely, PD-L1 rs822339, PD-L1 rs1411262, and PD-L1 rs2282055 were in strong LD 
(Supplementary Fig. S1), therefore it is possible that these haplotypes might affect the efficacy of nivolumab.
Figure 2. Best overall responses in all patients in this cohort with nivolumab. The blue lines represent the 
C/C genotype, the green lines represent the C/G genotype, and the red lines represent the G/G genotype of 
PD-L1 rs4143815. Duration of best overall responses and changes in target lesions from baseline in 50 patients 
who received nivolumab.
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In this study, we focused on the PD-1/PD-L1 SNPs as a predictive biomarker of nivolumab since the PD-1/
PD-L1 pathway is involved in the immune system. The PD-1 receptor, which is broadly expressed in multiple 
cell types, including T- and B-cells, dendritic cells, and macrophages36, plays a role in down-regulating T-cell 
responses37,38 and leads to immune suppression instead of activation. So far, the function of the PD-L1 polymor-
phism has not been fully investigated; however, it may modify anti-tumor immunity and affect the response to 
chemotherapy or immune checkpoint inhibitors.
This study had several limitations. First, this was a retrospective study with a small sample size and the patients 
who had received nivolumab were already relatively heavily pre-treated. Nevertheless, we showed a clinically 
meaningful difference in response rates and PFS among the PD-L1 rs4143815 and rs2282055 genotypes. Second, 
since this study lacks in immunohistochemical information from biopsies, the association between the PD-L1 
rs4143815 genotypes and the PD-L1 expression in tumor cells is unknown in this cohort. Although PD-L1 
expression is an important biomarker, we did not assess its expression in this study. The reason for this is due 
to the use of different antibodies in immunohistochemistry assays and the varying cut-off values to evaluate the 
expression of PD-L1, which make it difficult to compare with other studies. Third, we selected seven PD-1/PD-L1 
polymorphisms that are thought to be functional based on previous reports; however, there may be other, more 
efficient predictive SNP biomarkers.
The association between PD-L1 SNPs and the efficacy of nivolumab in a large-sized study needs to be investi-
gated in the future. We are planning future studies to assess the association of PD-L1 expression, PD-L1 SNPs and 
efficacy of anti-cancer treatment in order to confirm the observations presented in this study.
In conclusion, we found that in advanced stage NSCLC patients who received nivolumab, the C allele of 
PD-L1 rs4143815 and the G allele of rs2282055 were significantly associated with better ORR and PFS. This is 
the first report that PD-L1 SNP, which was thought to increase PD-L1 expression, is associated with a response 
to nivolumab. Therefore, these results suggests that PD-L1 rs4143815 and rs2282055 may be a biomarker for 
identifying patients for whom nivolumab may be particularly beneficial, which, as a result, may contribute to the 
clinical setting in the treatment of lung cancer.
Patients and Methods
Patients. Between December 2015 and August 2016, a total of 67 consecutive patients with histologically or 
cytologically confirmed NSCLC were treated with nivolumab. Among these 67 patients, we enrolled 50 patients 
in this study, all of whom were registered at Kyoto University Hospital. The remaining 17 patients were excluded 
from this study as a result of lack of DNA samples, discontinued observation due to change in hospital, the ina-
bility to obtain informed consent, or the patient had a history of double cancer. Participants in this study have 
provided a written informed consent and all experimental methods were in accordance with the 1975 Declaration 
of Helsinki. The study was approved by the Review Board of Kyoto University Hospital. A 10-mL peripheral blood 
sample was collected from each study participant. This procedure was performed in accordance with the ethical 
principles for medical research.
Genotyping and SNP selection. Genomic DNA was extracted from peripheral blood leukocytes using the 
GENE PREP STAR NA-480 (KURABO, Osaka, Japan) according to the manufacturer’s instructions. Genotyping 
was performed using the TaqMan® genotyping assay (Applied Biosystems, Foster City, CA) and analyzed with an 
Applied Biosystems 7300 Real-Time PCR System (Applied Biosystems). The polymerase chain reaction (PCR) 
solution included 12.5 μ L of 2X TaqMan Universal PCR Master Mix, 0.3125 μ L of primer probe mix, 11.2 μ L of 
nuclease-free water, and 1 μ L of DNA sample. After baseline fluorescence measurements at 25 °C, the PCR proto-
col included a 10-min incubation at 95 °C, 40 cycles of denaturing at 92 °C for 15 s and annealing and extending 
at 60 °C for 1 min, and a final measurement of fluorescence at 60 °C. SNPs with previously described associations 
or putative functional effects were selected24–28,39–43.
Evaluation of Nivolumab Efficacy. Medical records were reviewed and data extracted based on clinical 
features and treatment histories. These data have been updated as of October 2016. The initial dose of nivolumab 
was 3 mg/kg every two weeks and was intravenously administered until the assessment of progressive disease 
(PD) or an unacceptable toxicity level was reached. Radiographic imaging was done every 4 to 6 weeks. Response 
was assessed as per the Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1) by an investigator. 
The PFS was measured from the start of nivolumab administration until the date of RECIST PD. Patients without 
documented clinical or radiographic disease progression were censored on the date of the last follow-up. The 
ORR, as determined by the RECIST criteria, was calculated as the total percentage of patients with a complete or 
partial response (PR).
Statistical analysis. The JMP Pro statistical software version 12.1.0 (SAS Institute Inc, Tokyo, Japan) was 
used for all statistical analyses. Differences in characteristics among the genotypes were compared using Fisher’s 
exact test for categorical data. Genotypes were analyzed separately and as combined allelic groups. Clinical 
responses among the genotypes were analyzed using the Cochrane-Armitage test. The patient’s baseline charac-
teristics and the genotype of rs4143815 or rs2282055 were analyzed using one-way analysis of variance (ANOVA) 
for continuous variables.
The survival curves were estimated using the Kaplan-Meier method. Statistical significance of the relation-
ship between PFS and genetic polymorphism was assessed using the trend log-rank-test. Multivariate Cox pro-
portional hazards models were used to estimate adjusted hazard ratios (HR) with 95% confidence intervals. 
Multivariable regressions analysis was adjusted for age, gender, and histology. Haploview v4.2 was used to calcu-
late the linkage disequilibrium (LD), expressed as D’ and r2.
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